Abbott price target raised to $146 from $141 at Raymond James

Raymond James raised the firm’s price target on Abbott (ABT) to $146 from $141 and keeps an Outperform rating on the shares. Despite organic revenue growth and EPS that hit consensus, there was an expectation for more, and while Med Devices is accelerating, the rest of the business is experiencing some lumpiness, the analyst tells investors in a research note. The firm continues to see a 7%-8% organic revenue grower capable of growing 10%+ on the bottom-line.